Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

The synthesis and biological evaluation of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives

Ren-Jun Li, Yan Zhou, Yang Zheng, Li Hai* and Yong Wu* □

Leave this area blank for abstract info.

18 examples, up to 96% yield

$\text{R} = \text{C}_6\text{H}_5, 4\text{-ClC}_6\text{H}_4, 4\text{-MeC}_6\text{H}_4, 3,5\text{-Cl}_2\text{C}_6\text{H}_3$;

$\text{R}^1 = \text{H}, \text{CH}_3, \text{CH}(\text{CH}_3)_2$;

$\text{R}^2 = \text{H}, 6\text{-Cl}, 6\text{-OCH}_2\text{CONH}_2, 6\text{-OCH}_2\text{CO}_2\text{Et}$;

$\text{R}^3 = \text{H}, \text{CH}_3, \text{CH}(\text{CH}_3)_2$;

$\text{R}^4 = \text{H}, 5\text{-Br}, 5\text{-OH}, 5\text{-CN}, 6\text{-OCH}_2\text{CONH}_2, 6\text{-OCH}_2\text{CO}_2\text{H}, 6\text{-OCH}_2\text{CO}_2\text{Et}, 6\text{-OCH}_2\text{CONHMe}, 6\text{-OCH}_2\text{CONHOH}$.

The synthesis and biological evaluation of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives

Ren-Jun Li, Yan Zhou, Yang Zheng, Li Hai*, Yong Wu*

Key Laboratory of Drug-Targeting of Education Ministry and Department of Medicinal Chemistry, West China School of Pharmacy, Sichuan University, Chengdu, 610041, P. R. of China.

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives

Indole

Unsymmetrical

AlCl₃

Antiproliferative activity

ABSTRACT

A mild and highly efficient method has been developed for the synthesis of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives by the regioselective Friedel-Crafts alkylation of 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives with various indoles catalyzed by AlCl₃ at room temperature in a short reaction time in high yields (up to 96%). All these compounds were screened for their antiproliferative activity against human colorectal carcinoma HCT116 cell line. The preliminary biological study showed that some of them exhibited moderate to good antiproliferative activity *in vitro*. Especially, compound **3e** exerted the most powerful antiproliferative activity even better than the positive control MDM-2/p53 antagonist Nutlin-3a.

2009 Elsevier Ltd. All rights reserved.

Introduction

Previous studies have demonstrated the potential of bisindolylmethanes (BIMS) derivatives that contain two indoles or substituted indole units in a molecule feature exhibit a wide range of biological and pharmacological activities such as antibacterial,¹ antimicrobial,² antifungal,³ antiparkinsonian,⁴ immunomodulator,⁵ antidiabetic,⁵ antiobesity,⁶ lipoprotein disorder,⁶ apoptosis in acute myelogenous leukemia (AML),⁷ vaginal spermicide.⁸ Some of the bisindolylmethane derivatives are used for estrogen metabolism in humans,⁹ in the treatment of fibromyalgia, chronic fatigue, and irritable bowel syndrome.¹⁰ (Fig. 1) In addition to this, diheteroaryl methanes are also used in the food industry,¹¹ while as triheteroaryl methanes are applied in non-linear optics and conducting polymers.¹² Particularly, the bisindolylmethane derivatives also appear to have anti-tumor properties,¹³ although the exact mechanisms remain unclear. These observations suggest that additional BIMS derivatives may possess antiproliferative functions capable of therapeutic applications, and are worthy of further development.

Due to their wide range of biological and pharmacological activities, industrial and synthetic applications, a number of methods have been reported for the synthesis of symmetrical bisindolylmethanes, whereas the highly efficient synthesis of unsymmetrical bisindolylmethanes derivatives remains a challenge and has received renewed attention of researchers interested in the discovery of improved protocols. Various groups

have reported the synthesis of unsymmetrical bisindolylmethanes (BIMS) derivatives using either lewis acids or protic acids, such as Me₃SiCl,¹⁴ CAN,¹⁵ *p*-TsOH,¹⁶ FeCl₃,¹⁷ chiral phosphoric acid,¹⁸ HBF₄-SiO₂,¹⁹ InBr₃,²⁰ chiral imidodiphosphoric acids,²¹ as well as a leaving group strategy²² is employed. Though the reported methods are satisfactory, some of the methods suffer from certain drawbacks such as need of expensive catalysts,^{18, 20, 21} longer reaction time,^{14, 15, 16, 18} harsh reaction conditions (e.g., high temperatures),^{20, 22} cumbersome work-up procedures^{17, 19, 22} and poor yield¹⁶ of the desired product. In this context the development of an efficient and rapid method for the synthesis of bisindolylmethanes under mild reaction conditions is highly desirable.

In our initial research, we have shown efficient Brønsted acid-catalyzed regioselective Friedel-Crafts hydroxyalkylation of *N*-substituted glyoxylamide with indoles to afford the 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-substituted acetamide and the symmetrical bisindole.²³ In the present article, we report a facile route using AlCl₃ as an efficient catalyst and 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-substituted acetamide as the substance for the synthesis of widespread range of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives. The main objective of this work thus comprised the synthesis of novel 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives and their preliminary antiproliferative activity to assess the potential of these new

* Corresponding author. Tel: +86 028 85506666; Fax: +86 028 85506666; E-mail: smile@scu.edu.cn

* Corresponding author. Tel: +86 028 85503235; Fax: +86 028 85503235; E-mail: wyong@scu.edu.cn

Figure 1. Selected biologically active molecules containing bisindolylmethanes (BIMS) moiety.

Figure 2. The template of Trisindoline used for structural modification.

scaffolds as they are the open chain analogues of trisindoline^{13c} for more elaborate studies in the future. (**Fig. 2**)

Results and discussion

At the beginning of our study, the screening of reaction conditions was focused on a variety of reaction parameters by using a model reaction of *N*-(4-chlorophenyl)-2-hydroxy-2-(1*H*-indol-3-yl)acetamide (**1a**) with 5-bromine indole (**2a**). The results were summarized in **Table 1**. Various Lewis acid such as SnCl₂, FeCl₃, AlCl₃, CuCl₂, Cu(CF₃SO₃)₂, Fe(CF₃CO₂)₃, SnCl₄, NiCl₂, ZnCl₂, FeSO₄, CoCl₂, AgSbF₆, Ce(NO₃)₃ and MnCl₂ were used. Among these catalysts, AlCl₃ exhibited the higher activity (Table 1, entry 3, 87% yield). Furthermore, other aluminium salts such as Al(NO₃)₃ (Table 1, entry 15, 84% yield) and Al₂(SO₄)₃ (Table 1, entry 16, 83% yield) were used, forming the desired product **3a** in a nearly high level of yield as catalyzed by AlCl₃. In terms of the optimal amount of AlCl₃ needed in the model reaction, it is found that the yield of desired product **3a** increased to 96% (Table 1, entry 17) when 50 mmol% AlCl₃ was used, while the yield of **3a** increased to nearly 92% when 100 mmol% AlCl₃ was used (Table 1, entry 18). Therefore, using 50 mmol% AlCl₃ was found to be more effective.

Further investigation indicated that temperature was important for this transformation. An excellent yield had been obtained when the reaction was carried out at 25 °C (Table 1, entry 17). However, when the reaction temperature increased to 50 °C and even higher to 80 °C, the yield of the desired product **3a** dropped to 74% and 57% (Table 1, entries 19-20). Among various solvents examined, C₂H₅OH turned out to be the best choice, while others such as THF, CH₃CN, DMF, dioxane, acetone, toluene, CH₂Cl₂, CH₃COOC₂H₅ were less effective (Table 1, entries 17 and 21-28). We did not find the desired increment of product **3a** when the reaction time was extended to 24h (Table 1, entry 29) or 2 equivalents of **2a** was added (Table 1, entry 30).

Therefore, in concerns of catalytic selectivity and level of yield, we could obtain the product **3a** with 96% yield by using 50 mmol% AlCl₃ as catalyst and C₂H₅OH as the solvent.

Table 1. Screening studies for the regioelective Friedel-Crafts alkylation of 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives with indoles ^a

Entry	Catalyst (mmol%)	Solvent	Temp (°C)	Yield ^b (%)
1	SnCl ₂ (10)	C ₂ H ₅ OH	25	60
2	FeCl ₃ (10)	C ₂ H ₅ OH	25	70
3	AlCl ₃ (10)	C ₂ H ₅ OH	25	87
4	CuCl ₂ (10)	C ₂ H ₅ OH	25	70
5	Cu(CF ₃ SO ₃) ₂ (10)	C ₂ H ₅ OH	25	48
6	Fe(CF ₃ CO ₂) ₃ (10)	C ₂ H ₅ OH	25	Trace
7	SnCl ₄ (10)	C ₂ H ₅ OH	25	80
8	NiCl ₂ (10)	C ₂ H ₅ OH	25	8
9	ZnCl ₂ (10)	C ₂ H ₅ OH	25	5
10	FeSO ₄ (10)	C ₂ H ₅ OH	25	Trace
11	CoCl ₂ (10)	C ₂ H ₅ OH	25	18
12	AgSbF ₆ (10)	C ₂ H ₅ OH	25	71
13	Ce(NO ₃) ₃ (10)	C ₂ H ₅ OH	25	82
14	MnCl ₂ (10)	C ₂ H ₅ OH	25	20
15	Al(NO ₃) ₃ (10)	C ₂ H ₅ OH	25	84
16	Al ₂ (SO ₄) ₃ (10)	C ₂ H ₅ OH	25	83
17	AlCl ₃ (50)	C ₂ H ₅ OH	25	96
18	AlCl ₃ (100)	C ₂ H ₅ OH	25	92
19	AlCl ₃ (50)	C ₂ H ₅ OH	50	74
20	AlCl ₃ (50)	C ₂ H ₅ OH	80	57
21	AlCl ₃ (50)	THF	25	88
22	AlCl ₃ (50)	CH ₃ CN	25	87
23	AlCl ₃ (50)	DMF	25	60
24	AlCl ₃ (50)	Dioxane	25	89
25	AlCl ₃ (50)	Acetone	25	81
26	AlCl ₃ (50)	Toluene	25	Trace
27	AlCl ₃ (50)	CH ₂ Cl ₂	25	Trace
28	AlCl ₃ (50)	CH ₃ COOC ₂ H ₅	25	46
29 ^c	AlCl ₃ (50)	C ₂ H ₅ OH	25	90
30 ^d	AlCl ₃ (50)	C ₂ H ₅ OH	25	94

^a Unless noted otherwise, reactions were performed with **1a** (1.0 mmol), **2a** (1.1 mmol) and catalyst in 8 mL solvent were stirred at the corresponding temperature for 0.5 h.

^b Isolated yield.

^c Reaction time was 24h.

^d **2a** (2.0 mmol) was added.

Table 2. Substrate scope in regioselective Friedel-Crafts alkylation of 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives with indoles using AlCl₃ as the catalyst ^a

Entry	R	R ¹	R ²	R ³	R ⁴	Product	Yield (%) ^b
1	4-ClC ₆ H ₄	H	H	H	5-Br	3a	96
2	4-ClC ₆ H ₄	H	H	CH ₃	6-OCH ₂ CO ₂ Et	3b	93
3	4-ClC ₆ H ₄	H	H	CH(CH ₃) ₂	6-OCH ₂ CO ₂ Et	3c	92
4	4-ClC ₆ H ₄	H	6-Cl	CH ₃	6-OCH ₂ CO ₂ Et	3d	89
5	4-ClC ₆ H ₄	H	6-Cl	H	5-OH	3e	90
6	4-ClC ₆ H ₄	H	6-Cl	CH ₃	6-OCH ₂ CONH ₂	3f	84
7	4-ClC ₆ H ₄	CH ₃	6-OCH ₂ CONH ₂	CH(CH ₃) ₂	6-OCH ₂ CO ₂ H	3g	81
8	4-ClC ₆ H ₄	H	6-Cl	CH ₃	6-OCH ₂ CONHMe	3h	82
9	4-ClC ₆ H ₄	CH ₃	6-OCH ₂ CO ₂ Et	H	5-OH	3i	79
10	4-ClC ₆ H ₄	CH ₃	6-OCH ₂ CO ₂ Et	CH ₃	6-OCH ₂ CONH ₂	3j	78
11	4-MeC ₆ H ₄	H	6-Cl	CH ₃	6-OCH ₂ CO ₂ Et	3k	80
12	4-MeC ₆ H ₄	H	6-Cl	CH(CH ₃) ₂	6-OCH ₂ CO ₂ H	3l	76
13	4-MeC ₆ H ₄	CH(CH ₃) ₂	6-OCH ₂ CONH ₂	H	5-OH	3m	74
14	4-MeC ₆ H ₄	CH ₃	6-OCH ₂ CO ₂ Et	CH(CH ₃) ₂	6-OCH ₂ CONH ₂	3n	79
15	3,5-Cl ₂ C ₆ H ₃	H	6-Cl	CH(CH ₃) ₂	6-OCH ₂ CONH ₂	3o	82
16	3,5-Cl ₂ C ₆ H ₃	H	6-Cl	CH(CH ₃) ₂	6-OCH ₂ CONHOH	3p	71
17	3,5-Cl ₂ C ₆ H ₃	CH ₃	6-OCH ₂ CO ₂ Et	H	5-CN	3q	68
18	C ₆ H ₅	CH ₃	6-OCH ₂ CO ₂ Et	CH(CH ₃) ₂	6-OCH ₂ CONH ₂	3r	74

^a Reaction conditions: 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives (**1**, 1.0 mmol), indole (**2**, 1.1 mmol), and 50 mmol% AlCl₃ in 8mL C₂H₅OH were stirred at room temperature for 0.5 h.

^b Isolated yield.

With the optimized conditions in hand, a series of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives resulting from the regioselective Friedel-Crafts alkylation were thus carried out. The results were summarized in **Table 2**. Among the tested substrates, a variety of 2-hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives with indoles owning different substituents bearing either the electron-donating groups such as methyl, isopropyl and alkoxy at the 1- and 6-positions, or electron-withdrawing groups such as bromo and cyano at the 5-position, were well tolerated during the course of the reaction providing the desired products **3a-3r** in moderate to good yields.

The 17 novel 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives were then evaluated for their *in vitro* antiproliferative activity using MTT assay on human HCT116 colorectal carcinoma cell line. The preliminary biological study showed that seven of the prepared 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives displayed antiproliferative activity against the HCT116 colorectal carcinoma cell (**3e**, **3l**, **3n**, **3o**, **3p**, **3q**, **3r**). Furthermore, among all the screened compounds, the compound **3e** containing the moiety of 5-hydroxyindole and 6-chloroindole exhibited better antiproliferative activity as compared to the positive control MDM-2/p53 antagonist Nutlin-3a²⁴ (the IC₅₀ value described in the literature was 0.09 μM) at the screening concentration of 10 μM. (See the SM for full details)

Conclusion

In conclusion, we have developed a mild and highly efficient method for the synthesis of unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives from various indoles and 2-

hydroxy-2-(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives using 50 mol % of AlCl₃ in C₂H₅OH. The advantages of this method include its simplicity, clean reactions, high yields, short reaction time and use of inexpensive catalyst. The simple catalytic system worked well with a broad range of indoles and allowed the facile synthesis of appropriately substituted unsymmetrical 2,2-di(1*H*-indol-3-yl)-*N*-phenylacetamide derivatives. All these compounds were screened for their antiproliferative activity against human colorectal carcinoma HCT116 cell line. The preliminary biological study showed that some of them exhibited moderate to good antiproliferative activity *in vitro*. Especially, compound **3e** exerted the most powerful antiproliferative activity even better than the positive control MDM-2/p53 antagonist Nutlin-3a suggesting that these scaffolds could be further developed as possible antiproliferative agents by the structural modification in both indole and acetanilide moieties for improving their antiproliferative efficacy. The complete structural modification and biological study are in research.

Acknowledgments

We sincerely thank the National Science Foundation of China (No.81373259 & No. 21472130) for financial support of this study.

Supplementary Material

Supplementary data associated with this article can be found, in the online version, at.

References and notes

1. Bell, R.; Carmeli, S.; Sar, N. J. *Nat. Prod.* **1994**, *57*, 1587-1590.
2. Sivaprasad, G.; Perumal, P. T.; Prabavathy, V. R.; Mathivanan, N. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 6302-6305.
3. Kamal, A.; Khan, M. N. A.; Srinivasa, R. K.; Srikanth, Y. V. V.; Kaleem, A. S.; Pranay, K. K.; Murthy, U. S. N. *J. Enzyme Inhib. Med. Chem.* **2009**, *24*, 559-565.
4. Miranda, D. B. R.; Miller, J. A.; Hansen, R. J.; Lunghofer, P. J.; Safe, S.; Gustafson, D. L.; Colagiovanni, D.; Tjalkens, R. B. *J. Pharmacol. Exp. Ther.* **2013**, *345*, 125-138.
5. Mjalli, A. M. M.; Shahbaz, K. G. J. WO 2003032982, 2003.
6. Sashidhara, K. V.; Kumar, M.; Sonkar, R.; Singh, B. S.; Khanna, A. K.; Bhatia, G. J. *Med. Chem.* **2012**, *55*, 2769-2779.
7. Contractor, R.; Samudio, I. J.; Estrov, Z.; Harris, D.; McCubrey, J. A.; Safe, S. H.; Andreeff, M.; Konopleva, M. *Cancer Res.* **2005**, *65*, 2890-2898.
8. Paira, P.; Hazra, A.; Kumar, S.; Paira, R.; Sahu, K. B.; Naskar, S.; Saha, P.; Mondal, S.; Maity, A.; Banerjee, S.; Mondal, N. B. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 4786-4789.
9. Karthik, M.; Mageshk, C. J.; Perumal, P. T. *Appl. Catal. A* **2005**, *286*, 137-141.
10. (a) Chakrabarty, M.; Ghosh, N.; Basak, R.; Harigaya, Y. *Tetrahedron Lett.* **2002**, *43*, 4075-4078; (b) Kamble, V. T.; Kadam, K. R.; Joshi, N. S.; Muley, D. B. *Catal. Commun.* **2007**, *8*, 498-502.
11. (a) Shimoda, M.; Shibamoto, T. *J. Agric. Food Chem.* **1990**, *38*, 802-804; (b) Gianturco, M. A.; Giammarino, A. S.; Friedel, P.; Flanagan, V. *Tetrahedron* **1964**, *20*, 2951-2961; (c) Stoll, M.; Winter, M.; Gautechi, F.; Flamment, I.; Willhalm, B. *Helv. Chim. Acta* **1967**, *50*, 628-694; (d) Katritzky, A. R.; Xie, L.; Fan, W. Q. *J. Org. Chem.* **1993**, *58*, 4376-4381.
12. (a) Shchepinov, M. S.; Korshun, V. A. *Chem. Soc. Rev.* **2003**, *32*, 170-180; (b) Noack, A.; Schröder, A.; Hartmann, H. *Dyes Pigm.* **2002**, *57*, 131-147; (c) Brasselet, S.; Cherioux, F.; Audebert, P.; Zyss, J. *Chem. Mater.* **1999**, *11*, 1915-1920; (d) Cherioux, F.; Guyard, L.; Audebert, P. *Adv. Mater.* **1998**, *10*, 1013-1018.
13. (a) Kamal, A.; Srikanth, Y. V.; Khan, M. N.; Shaik, T. B.; Ashraf, M. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5229-5231; (b) Subba, R. B. V.; Rajeswari, N.; Sarangapani, M.; Prashanthi, Y.; Ganji, R. J.; Addlagatta, A. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 2460-2463; (c) Yoo, M.; Choi, S. U.; Choi, K. Y.; Yon, G. H.; Chae, J. C.; Kim, D.; Zylstra, G. J.; Kim, E. *Biochem. Biophys. Res. Commun.* **2008**, *376*, 96-99.
14. Denis, J. N.; Mauger, H.; Vallée, Y. *Tetrahedron Lett.* **1997**, *38*, 8515-8518.
15. Zeng, X. F.; Ji, S. J.; Wang, S. Y. *Tetrahedron* **2005**, *61*, 10235-10241.
16. Pathak, T. P.; Osiak, J. G.; Vaden, R. M.; Welm, B. E.; Sigman, M. S. *Tetrahedron* **2012**, *68*, 5203-5208.
17. Niu, T. M.; Huang, L. H.; Wu, T. X.; Zhang, Y. H. *Org. Biomol. Chem.* **2011**, *9*, 273-277.
18. (a) Fu, A. P.; Meng, W.; Li, H. L.; Nie, J.; Ma, J. A. *Org. Biomol. Chem.* **2014**, *12*, 1908-1918; (b) Sun, F. L.; Zheng, X. J.; Gu, Q.; He, Q. L.; You, S. L. *Eur. J. Org. Chem.* **2010**, *2010*, 47-50.
19. Bandgar, B. P.; Patil, A. V.; Kamble, V. T. *ARKIVOC* **2007**, 252-259.
20. Lin, H.; Zang, Y.; Sun, X. W.; Lin, G. Q. *Chin. J. Chem.* **2012**, *30*, 2309-2314.
21. Zhuo, M. H.; Jiang, Y. J.; Fan, Y. S.; Gao, Y.; Liu, S.; Zhang, S. Q. *Org. Lett.* **2014**, *16*, 1096-1099.
22. Li, M. H.; Taheri, A.; Liu, M.; Sun, S. H.; Gu, Y. L. *Adv. Synth. Catal.* **2014**, *356*, 537-556.
23. Zhan, Z.; Li, R. J.; Zheng, Y.; Zhou, Y.; Hai, L.; Wu, Y. *Synlett* **2015**, *26*, 2261-2266.
24. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. *Science*, **2004**, *303*, 844-848.